Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 -- For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly better survival than chemotherapy, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2024 Category: Pharmaceuticals Source Type: news
Q & A: Immunotherapy in Renal Cell Carcinoma (RCC) Q & A: Immunotherapy in Renal Cell Carcinoma (RCC)
A collaboration and conversation between Medscape and Dr Karl D ' Silva on the impact of immunotherapy in renal cell carcinoma.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
First-Line Nivolumab Plus Chemo Approved for Bladder Cancer
(MedPage Today) -- The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
On March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 7, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news
Quality of life of patients treated with robotic surgery in the oral and maxillofacial region: a scoping review of empirical evidence
ConclusionCompared
to the conventional treatment modalities, TORS has demonstrated better
QoL, mostly in the domains related to oral functions such as swallowing
and speech, among patients treated with such. This improvement was most
evident within the initial post-operative year. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 7, 2024 Category: Dentistry Source Type: news
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) Mar 07, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2024 Category: Drugs & Pharmacology Source Type: news
Advancing Equity: Tailored Treatments for Renal Cell Carcinoma Advancing Equity: Tailored Treatments for Renal Cell Carcinoma
Dr Jose A. Karam addresses health disparities in RCC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2024 Category: Consumer Health News Tags: None MDAngle Source Type: news
Novel Therapy Promising for Radiation-Induced Oral Mucositis
(MedPage Today) -- The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck who underwent radiation therapy, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news
Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- Gene-guided treatment selection for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) failed to improve disease control versus random treatment selection in a small preliminary clinical trial.
Personalized treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 4, 2024 Category: Hematology Source Type: news
ECR: Momentum gathers for abbreviated MRI in high-risk breast screening
Abbreviated breast MRI is not only effective for screening among high-risk women but also useful for evaluating "pure" ductal carcinoma in situ (DCIS), according to two presentations delivered March 2 at ECR 2024.
The shortened protocol offers patients a safe alternative to longer breast MRI screening exams – and streamlines radiology department workflow, said first presenter Dr. Tamara Suaris of St. Bartholomew's Hospital in London.
"Abbreviated breast MRI can be considered as a safe alternative to conventional MRI studies [for] very high-risk screening, reducing MR waiting times and backlog," she noted.
Abbreviated ...
Source: AuntMinnie.com Headlines - March 4, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News MRI Source Type: news
Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC
(MedPage Today) -- More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small clinical trial showed.
LRC at... (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - March 1, 2024 Category: Radiology Source Type: news
Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results
(MedPage Today) -- Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results.
While first-line pembrolizumab plus... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 1, 2024 Category: Hematology Source Type: news
ECR: Coronal reconstruction on ABUS helps avoid false negatives
Careful consideration of results from coronal reconstruction on automated breast ultrasound (ABUS) can help clinicians avoid false negatives, according to study results shared February 29 at ECR 2024.
The fact that ABUS is capable of this 3D technique differentiates it from handheld ultrasound, said presenter Elizabet Nikolova, MD, of University Hospital of Zürich in Switzerland. In a study she conducted with colleagues, two women were diagnosed with invasive carcinoma on follow-up after initial ultrasound findings were classified as BI-RADS 2.
"Both lesions were already visible in previous ABUS and mammography and the...
Source: AuntMinnie.com Headlines - March 1, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Ultrasound Source Type: news
Inadequate Knowledge: HPV and Oropharyngeal Carcinoma Inadequate Knowledge: HPV and Oropharyngeal Carcinoma
Dr Maurie Markman discusses a recent paper investigating knowledge about the relationship between HPV and oropharyngeal squamous cell carcinoma.Medscape Oncology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 29, 2024 Category: Infectious Diseases Tags: Hematology-Oncology Commentary Source Type: news
